Immunovant, Inc. (NASDAQ:IMVT - Get Free Report) CEO Peter Salzmann sold 4,460 shares of the stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $29.56, for a total value of $131,837.60. Following the transaction, the chief executive officer now owns 1,003,884 shares of the company's stock, valued at $29,674,811.04. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Peter Salzmann also recently made the following trade(s):
- On Wednesday, July 17th, Peter Salzmann sold 8,685 shares of Immunovant stock. The shares were sold at an average price of $29.69, for a total value of $257,857.65.
Immunovant Trading Up 1.6 %
NASDAQ:IMVT opened at $30.40 on Friday. Immunovant, Inc. has a twelve month low of $24.67 and a twelve month high of $45.58. The company has a market cap of $4.45 billion, a price-to-earnings ratio of -15.75 and a beta of 0.66. The stock has a fifty day simple moving average of $29.95 and a 200-day simple moving average of $29.08.
Immunovant (NASDAQ:IMVT - Get Free Report) last released its earnings results on Tuesday, August 6th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.07). During the same period last year, the company posted ($0.57) earnings per share. As a group, equities research analysts predict that Immunovant, Inc. will post -2.43 EPS for the current fiscal year.
Analyst Ratings Changes
Watch this before it gets removed
From Porter & Company | Ad
If you missed it, my emergency election broadcast is now available - watch it before it's too late.
Click here to watch it now.
IMVT has been the subject of a number of research reports. UBS Group lowered their target price on Immunovant from $42.00 to $41.00 and set a "buy" rating for the company in a research report on Tuesday, August 13th. JPMorgan Chase & Co. lowered their price target on Immunovant from $51.00 to $46.00 and set an "overweight" rating for the company in a research report on Thursday, August 8th. Raymond James restated an "outperform" rating and issued a $36.00 price target on shares of Immunovant in a research report on Thursday. Cantor Fitzgerald restated an "overweight" rating on shares of Immunovant in a research report on Monday, September 9th. Finally, Oppenheimer raised their price target on Immunovant from $47.00 to $53.00 and gave the stock an "outperform" rating in a research report on Wednesday. Twelve analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $48.58.
Read Our Latest Report on IMVT
Hedge Funds Weigh In On Immunovant
Several institutional investors have recently made changes to their positions in IMVT. Octagon Capital Advisors LP increased its stake in shares of Immunovant by 127.3% during the fourth quarter. Octagon Capital Advisors LP now owns 273,289 shares of the company's stock valued at $11,514,000 after buying an additional 1,273,289 shares during the period. Wellington Management Group LLP increased its stake in shares of Immunovant by 75.0% during the fourth quarter. Wellington Management Group LLP now owns 295,020 shares of the company's stock valued at $12,429,000 after buying an additional 126,412 shares during the period. Los Angeles Capital Management LLC increased its stake in shares of Immunovant by 185.4% during the first quarter. Los Angeles Capital Management LLC now owns 14,371 shares of the company's stock valued at $464,000 after buying an additional 9,335 shares during the period. Allspring Global Investments Holdings LLC increased its stake in shares of Immunovant by 51.9% during the first quarter. Allspring Global Investments Holdings LLC now owns 65,091 shares of the company's stock valued at $2,103,000 after buying an additional 22,226 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Immunovant by 66.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 27,936 shares of the company's stock valued at $903,000 after buying an additional 11,202 shares during the period. Hedge funds and other institutional investors own 47.08% of the company's stock.
Immunovant Company Profile
(
Get Free Report)
Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
